Definitive Healthcare (NasdaqGS:DH) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsCasey Heller - CFOJonathan Paris - Chief Legal Officer and SecretaryKevin Coop - CEO and Board MemberConference Call ParticipantsBrian Peterson - Managing Director and Senior Equity Research AnalystGeorge Hill - Managing Director and Senior Equity Research AnalystJared Haase - Equity Research AnalystJeff Garro - Equity Research AnalystMatt Shea - Equity Research AnalystNone - AnalystJonathan ParisGood ...

Financial Data and Key Metrics Changes - For the first three quarters of 2025, total revenue reached CNY 2.57 billion, a year-on-year increase of 23.1, while net profit attributable to ordinary shareholders was approximately CNY 410 million, rising 51.9% compared to the same period last year [1] - The company reported total revenue of CNY 975 million for the third quarter, marking a year-on-year growth of 38.4 [13] - Operating profit for the quarter was nearly CNY 114 million, reflecting a substantial year-over-year increase of 329.8%, with net profit attributable to ordinary shareholders reaching CNY 158 million, up 60.1% year-over-year [15] Business Line Data and Key Metrics Changes - The insurtech business achieved an operating profit of about CNY 180 million in the quarter, a year-on-year increase of 44.3% [1] - Insurance-related revenue reached approximately CNY 870 million, increasing by 44.8% year-on-year and 17.8% quarter-on-quarter, with an operating profit margin of 20.3% [4] - Profiling service fees stood at around CNY 65.66 million, remaining stable year-on-year, while digital clinical trial solutions contributed over CNY 31.85 million, with a year-on-year increase of 31.3% [14] Market Data and Key Metrics Changes - As of September 30, 2025, the cumulative registrations for the medical profiling platform reached approximately 485 million, with a total of CNY 71.2 billion raised for 3.61 million patients [9] - The digital clinical trial solution income in the third quarter reached CNY 31.85 million, marking a 31.3% year-on-year increase [12] Company Strategy and Development Direction - The company is focused on leveraging advancing AI technologies to drive integration and innovation across operations, aiming for sustainable long-term growth [4] - The launch of Waterdrop C-Point AI, a low-code AI platform, is intended to empower employees to build and deploy tailored solutions for various tasks, supporting growth in both insurance and non-insurance areas [2] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in exceeding full-year revenue and profit guidance, emphasizing the importance of AI in enhancing operational efficiency and decision-making [4] - The company highlighted its commitment to sustainable development and creating value for society through its various initiatives [2] Other Important Information - The company has filed 69 patent applications centered on large language models, including nine international filings, indicating a strong focus on innovation [2] - As of the end of November 2025, the company had repurchased approximately 58.1 million ADS in the open market, totaling $113 million [3] Q&A Session Summary Question: What are the key drivers of growth in the insurance business? - The insurance business maintained significant growth momentum, with optimized real-time identification capabilities and enhanced integration of data links among advertising, operation, and risk control systems [4] Question: How is the company addressing operational efficiency? - The deployment of AI across various services has significantly improved operational efficiency, with AI medical insurance experts boosting productivity and response times [7][8]

Core Viewpoint - The company, Beitong Shuzhi, has submitted its listing application to the Hong Kong Stock Exchange, leveraging its innovative Direct Data Integration (DDI) solution and extensive data accumulation to establish a significant position in the healthcare data empowerment industry. However, the company faces notable risks and challenges related to industry dependence, data compliance, customer concentration, and R&D investment [1]. Group 1: Core Advantages and Market Position - Beitong Shuzhi is a leading data empowerment provider in China's healthcare sector, with a comprehensive intelligent data platform covering the entire product lifecycle and integrating all channels in the pharmaceutical distribution field [2]. - The company pioneered the DDI solution in 2009, enhancing data accuracy and traceability while supporting channel regulation and compliance management. According to Frost & Sullivan, Beitong Shuzhi ranks second among third-party digital service providers in the pharmaceutical and medical device sectors in China based on projected revenue for 2024 [2]. - The company has maintained steady revenue growth over the past three years, with revenues of RMB 221 million, RMB 241 million, RMB 243 million, and RMB 125 million for the years 2022, 2023, 2024, and the first half of 2025, respectively. Gross profits for the same periods were RMB 108 million, RMB 120 million, RMB 129 million, and RMB 59 million, with gross margins of 48.9%, 49.9%, 53.3%, and 49.2% [2][3]. Group 2: Industry Dependence and Customer Concentration Risk - The company's business is highly reliant on the healthcare industry, particularly pharmaceutical and medical device companies. Changes in industry policies, budget cuts, or mergers can directly impact client spending and revenue [5]. - The revenue contribution from the top five clients was 26.0%, 26.3%, and 23.5% for the years 2022, 2023, and 2024, respectively, with the largest single client accounting for approximately 6%. Although this percentage is decreasing, contracts are typically renewed annually, and clients can reduce budgets at any time [5]. Group 3: R&D Investment Uncertainty - As a technology-driven company, Beitong Shuzhi invests heavily in R&D, with expenses reaching RMB 45 million in 2023, accounting for 18.7% of revenue. The company acknowledges that R&D activities are time-consuming and costly, with no guarantee of success [6]. - R&D expenses for the years 2022 to 2024 were RMB 21.9 million, RMB 45 million, and RMB 36.9 million, representing 9.9%, 18.7%, and 15.2% of revenue, respectively, which is above the industry average. However, the high investment has not resulted in a strong patent portfolio, with only 11 invention patents and 170 software copyrights [6]. Group 4: Data Security and Compliance Challenges - The core business involves handling vast amounts of healthcare channel data, exposing the company to significant data security and compliance challenges. The listing document outlines risks such as data breaches from cyberattacks or internal misconduct [7]. - Although the company claims its data center has achieved a national information security level protection certification and has established internal control processes, any data security incident or compliance lapse could lead to reputational damage, client loss, and regulatory penalties [7]. Group 5: International Expansion and Geopolitical Risks - The company plans to expand into international markets, which will expose it to unfamiliar legal regulations, business environments, cultural differences, and geopolitical tensions, such as trade restrictions and economic sanctions [8]. - Uncertainties in international trade policies may affect the company's technology acquisition, supply chain stability, and market expansion plans [8].

Group 1 - The core viewpoint of the article is that Beitong Smart Cayman Holdings Limited has submitted an application to list on the main board of the Hong Kong Stock Exchange, with CCB International as its sole sponsor [1] - Beitong Smart is identified as a leading data empowerment provider in China's healthcare industry, focusing on leveraging vast data assets and industry expertise [1] - The company has developed a comprehensive intelligent data platform for the healthcare sector, aiming to cover the entire product lifecycle and achieve seamless integration across all channels in the pharmaceutical distribution field [1]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $60 million, down 4% year-over-year, but at the high end of guidance [4][17] - Adjusted EBITDA was $18.9 million, representing a margin of 32%, which was $2 million above the high end of guidance [4][21] - Unlevered free cash flow for the trailing 12 months was approximately $51 million [5][21] - Adjusted net income was $9.7 million, resulting in $0.07 of non-GAAP earnings per share [17][24] Business Line Data and Key Metrics Changes - Subscription revenues were $58.2 million, also down 4% year-over-year, but showed stabilization quarter-over-quarter [18] - Professional services revenue showed modest growth and was largely in line with expectations [18] - Total customer count remained steady at approximately 2,400, with enterprise customer count increasing to 520, the highest level since Q3 of the previous year [5][6] Market Data and Key Metrics Changes - Renewal rates showed year-over-year improvement, although it remains early to determine if this trend is durable [6][18] - Deferred revenue was $92 million, up 7% year-over-year, indicating a positive trend in customer commitments [22] Company Strategy and Development Direction - The company is focusing on four strategic pillars: differentiated data, seamless integrations, customer success, and digital partnerships [7][12] - There is an emphasis on enhancing data quality and expanding data sources to improve competitive positioning [7][8] - The company is investing in digital engagement and partnerships to drive future growth [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the macro environment, noting pressures on renewals but also improvements in operational metrics [54][56] - The company expects Q4 revenue to be between $59-$60 million, reflecting a decrease of 4%-5% compared to the same period last year [24] - For the full year, revenue guidance has been raised to $239-$240 million, indicating a 5% decline year-over-year [25] Other Important Information - The company has repurchased approximately 2 million shares for about $9 million, with $49 million remaining under the share repurchase authorization [22] - The integration of data into customer workflows is seen as critical for improving retention rates [10][11] Q&A Session Summary Question: Competitive takeaway regarding the medical device company - Management noted that there is strength in new logo acquisition and that competitive wins are becoming more common due to the quality of their data and integration capabilities [27][28] Question: Importance of new claims data - Management emphasized that claims data is crucial for product positioning and customer needs, with expectations for incremental growth from new data sources [29][30] Question: Changes in pharma clients' budget allocation - No notable changes were observed in budget allocation among biopharma clients, despite tighter budget constraints [32] Question: Improvements in downsell pressure - Management confirmed that downsell pressure remains isolated within the life sciences space, but renewal rates are improving [34][35] Question: Factors driving agency activations - The effectiveness of data in driving targeted marketing campaigns is leading to increased activations from agencies [37][39] Question: Future growth algorithm - Management indicated that future growth will be driven by both new customer acquisition and expansion within existing customers [46][49] Question: Expectations for renewals in December and January - Management acknowledged the significance of the upcoming renewal period and expressed cautious optimism based on recent improvements [54][58]

Economic Performance - In the past five years, five economic indicators in Pudong have surpassed the "trillion" mark, with three leading industries nearing half of the city's total [1] - By 2024, Pudong's GDP is projected to reach 1.78 trillion yuan, 1.34 times that of 2020, accounting for 32.9% of the city's total [2] - The total industrial output value is expected to be 1.32 trillion yuan, 1.27 times that of 2020, making up 33.6% of the city's total [2] - The total revenue from the service industry is anticipated to be 1.25 trillion yuan, 1.61 times that of 2020, representing 21.2% of the city's total [2] - The total import and export volume is projected to be 2.61 trillion yuan, 1.25 times that of 2020, accounting for 61.1% of the city's total [2] - Online retail sales are expected to reach 5.88 trillion yuan, 1.34 times that of 2020, making up 37.3% of the city's total [2] Industry Development - The three leading industries—integrated circuits, biomedicine, and artificial intelligence—achieved a scale of 832.3 billion yuan last year, accounting for 46% of the city's total, with an average annual growth rate of 11.7% over the past three years [3] - The proportion of strategic emerging industries in industrial output increased from 48.4% to 53.6% [2] Policy and Reform - Pudong has implemented three national strategic tasks with a landing rate of 93%, resulting in a series of innovative reforms and open results [4] - The "Systematic Opening Overall Plan" has seen 80 tasks largely implemented, with 77 pilot experiences replicated on a larger scale [4] - Key reforms include the first national pilot for importing remanufactured products and the implementation of localized management for imported medical device labels [4] Infrastructure and Urban Development - Pudong has invested 374.22 billion yuan in public welfare, maintaining a fiscal investment ratio of over 46% [6] - The "Five Rings" water system project aims to enhance ecological landscapes and urban functionality, covering an area of approximately 199.4 square kilometers and benefiting around 2.3 million residents [6] - The project includes the construction of new parks and green spaces, increasing the per capita park area to 13.4 square meters [6] Social Welfare and Community Development - The "Two Olds and One Village" renovation project has benefited 38,600 households, completing urban village transformations and improving living conditions [7]

Core Viewpoint - The establishment of a trusted data space in Guangzhou aims to enhance the integration and utilization of healthcare data, facilitating innovation in medical services and research while ensuring data privacy and security [1][2][3] Group 1: Data Products and Resources - The first batch of data products and high-quality datasets in Guangzhou includes five data products and 28 datasets related to various health conditions, such as pneumonia and liver cancer [1] - The projected outpatient volume for Guangzhou in 2024 is expected to reach 187 million, indicating significant potential in healthcare data resources [1] Group 2: Data Integration and Collaboration - The trusted data space connects hospitals, enterprises, and research institutions, establishing a data circulation mechanism to promote integrated governance and orderly flow of medical data [1][2] - Medical institutions are encouraged to share their data; for instance, a hospital has structured and anonymized seven specialized disease databases for integration into the trusted data space [2] Group 3: Data Utilization and Innovation - The trusted data space provides 100 petabytes of computing power to support algorithm training for hospitals, enabling innovation in general and specialized medical services [2] - Data from newborn jaundice cases is being utilized in collaboration with enterprises to validate and optimize algorithms for non-invasive jaundice testing [2] Group 4: Data Security and Privacy - The trusted data space implements privacy computing and audit mechanisms to ensure data does not leave the domain and its usage is traceable, addressing concerns about data misuse [2] - Each usage scenario requires a digital contract that specifies the purpose, permissions, and duration of data use, alleviating hospitals' concerns about potential data abuse [2] Group 5: Future Expansion Plans - The trusted data space currently covers 18 research hospitals in Guangzhou, with plans to expand its data resources and connect with at least 50 third-party data service providers and over 100 enterprises [3]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $59.2 million, down 7% year over year, but above the high end of guidance [5][21] - Adjusted EBITDA was $14.7 million, representing a 25% margin, which was well ahead of expectations [6][21] - Unlevered free cash flow for the trailing twelve months was $67.1 million, down 12% year over year, with a 91% conversion from adjusted EBITDA [27][28] Business Line Data and Key Metrics Changes - Subscription revenue declined 7% year over year, while Professional Services revenue grew by 9% in the quarter [23] - Adjusted gross profit was $47.1 million, down 11% from Q1 2024, with an adjusted gross profit margin of 79.5% [23] - Adjusted operating income was $12 million, down 35% from Q1 2024, with an adjusted EBITDA margin of 25% [26] Market Data and Key Metrics Changes - Renewal rates stabilized in Q1 at levels observed in the second half of 2024, but retention rates remain lower than desired [8][9] - New logo activity was solid across all end markets, indicating ongoing demand for differentiated actionable data [8] Company Strategy and Development Direction - The company is focusing on four strategic pillars: differentiated data, seamless integration, customer success, and digital engagement [9][18] - The goal is to improve retention rates and return to growth by enhancing the value proposition and performance across these areas [18] - The company is committed to managing costs while identifying additional ways to drive efficiencies [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in operational strategies despite economic uncertainties, aiming for sequential revenue growth in the near term [19] - The company is tightening its revenue guidance for 2025 to $234 million to $240 million, reflecting a 5% to 7% decline year over year [33] Other Important Information - The company repurchased approximately 5.6 million shares for a total of $21.2 million, leaving $77 million remaining under the existing authorization [29] - A goodwill impairment of $176.5 million was recorded due to stock price decline, which is a non-cash accounting charge [30] Q&A Session Summary Question: Can you elaborate on data integrations and their impact on retention? - Management indicated that data sharing and integration are crucial for enhancing customer retention, with a focus on facilitating data interactions through various platforms [37][39] Question: What is the agency strategy and its impact on the go-to-market motion? - The agency strategy is seen as applicable across all customer segments, aiming to leverage differentiated data to help customers activate their data effectively [41][43] Question: What is the expected timeframe for seeing growth inflection from operational changes? - Management expects to see signs of growth within the year as operational changes take effect, with a focus on aligning support functions and customer engagement [45][47] Question: How does the company plan to address churn and customer retention? - Management noted that while churn remains a challenge, stabilization is encouraging, and operational actions are expected to improve renewal rates later in the year [77][78] Question: What is the competitive environment like, especially against other pharma services companies? - Management acknowledged pressures in the Life Sciences sector due to macroeconomic factors but emphasized the company's focus on quality data as a competitive advantage [78][80]